Brief: Igc Pharma Breakthrough Preclinical Trial Data Shows Tgr-63 Reduces Plaque In Alzheimer’S
23/01/2024 15:41
Jan 23 (Reuters) - IGC Pharma Inc IGC.A :
* IGC PHARMA BREAKTHROUGH: PRECLINICAL TRIAL DATA SHOWS
TGR-63
REDUCES PLAQUE IN ALZHEIMER’S
Source text for Eikon: ID:nBw6ZMh2Ba
Further company coverage: IGC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment